8-K: SunOpta Q3 Revenue Soars 16.8%, But 2025 EBITDA Outlook Cut

SunOpta Inc. reported a 16.8% revenue increase in Q3 2025 driven by strong volume growth, but lowered its full-year 2025 Adjusted EBITDA guidance.

Summary

• Revenues from continuing operations increased 16.8% to $205.4 million in Q3 2025, up from $175.9 million in the prior year period, driven by strong volume growth across beverages, broths, and fruit snacks.
• Earnings from continuing operations were $0.8 million, a significant improvement from a loss of $6.2 million in the prior year period.
• Adjusted EBITDA from continuing operations increased 13.4% to $23.6 million, compared to $20.8 million in the prior year period.
• Adjusted earnings per share from continuing operations rose to $0.05 from $0.02 in the prior year period.
• Gross profit increased 11.4% to $25.5 million, but gross margin decreased by 60 basis points to 12.4% from 13.0% in the prior year.
• Adjusted gross margin was 13.6% for Q3 2025, down from 16.6% in Q3 2024, impacted by investments in labor and infrastructure, increased maintenance, higher waste and labor costs due to volume growth, and temporary volume limitations from a wastewater issue at the Midlothian, Texas facility.
• Operating income increased to $6.9 million from $0.8 million, primarily due to lower employee variable compensation and professional fees, partially offset by $2.6 million in non-cash asset impairment charges.
• Net leverage improved to 2.8x as of September 27, 2025, from 3.0x at the end of fiscal 2024, with expectations to maintain this ratio.
• Cash provided by operating activities of continuing operations for the first three quarters of fiscal 2025 was $34.1 million, up from $19.2 million in the prior year period.

Sentiment

Score: 6

Explanation: The strong revenue growth and strategic capacity investments are positive for long-term prospects. However, the significant reduction in 2025 Adjusted EBITDA guidance and ongoing operational challenges (supply chain stress, margin compression, wastewater issues) introduce near-term uncertainty and temper overall sentiment.

Positives

• Strong revenue growth of 16.8% to $205.4 million, driven by robust volume increases in beverages, broths, and fruit snacks.
• Return to profitability with earnings from continuing operations of $0.8 million, compared to a loss of $6.2 million in the prior year.
• Adjusted EBITDA from continuing operations increased 13.4% to $23.6 million, demonstrating improved operational performance.
• Adjusted EPS from continuing operations more than doubled to $0.05 from $0.02.
• Net leverage ratio improved to 2.8x from 3.0x at year-end fiscal 2024, indicating disciplined financial management.
• Announced a new aseptic manufacturing line at the Midlothian, Texas facility, already over 50% subscribed, to come online in late 2026, positioning the company to meet market demand through 2028.
• Cash provided by operating activities of continuing operations significantly increased to $34.1 million for the first three quarters of fiscal 2025.

Negatives

• Gross margin decreased by 60 basis points to 12.4% in Q3 2025 from 13.0% in Q3 2024.
• Adjusted gross margin declined to 13.6% from 16.6% in the prior year, attributed to investments in labor and infrastructure, increased maintenance, higher waste and labor costs due to rapid volume growth, and temporary volume limitations from a wastewater issue.
• The speed and magnitude of volume growth stressed the company's supply chain.
• Incurred non-cash asset impairment charges of $2.6 million related to the decommissioning of tote filling equipment and early retirement of non-production assets.
• Costs related to the exit from aseptic totes packaging, including $1.3 million in inventory write-offs and $0.1 million in employee severance costs.
• The company lowered its 2025 Adjusted EBITDA outlook to $90-$92 million from the prior range of $99-$103 million.

Risks

• The long-term tariff environment remains uncertain, despite current mitigation strategies, potentially impacting raw material sourcing and costs.
• Potential for supply chain, logistics, and other disruptions, exacerbated by rapid volume growth.
• Risk of unexpected issues or delays with structural improvements and automation investments, including the new aseptic manufacturing line.
• Failure or inability to implement portfolio changes, process improvements, go-to-market improvements, and process sustainability strategies in a timely manner.
• Exposure to local and global political and economic conditions, and changes in consumer spending patterns and market trends.
• Potential for decreases in customer demand or delayed/unsuccessful product development efforts.
• Challenges in working capital management and the availability and pricing of raw materials and supplies.
• Risk of potential covenant breaches under the Company's credit facilities.
• Impact of tariffs, including increases in food prices and inflation, and any resulting negative macroeconomic effects.

Future Outlook

SunOpta updated its 2025 revenue outlook to $812 $816 million, a slight increase from the prior range, but significantly lowered its 2025 Adjusted EBITDA outlook to $90 $92 million. The company provided an initial 2026 outlook, projecting revenues of $865 $880 million and Adjusted EBITDA of $102 $108 million. Management anticipates returning to planned gross margin expansion activities by mid-2026 and is investing in a new aseptic manufacturing line to meet expected market demand through the end of 2028.

Management Comments

• "We delivered outstanding revenue growth in the third quarter and affirmed the strength of our competitive position, the diversity of our revenue streams and the robust demand across our portfolio."
• "During the quarter, the combination of category tailwinds and several pipeline opportunities, that were originally anticipated for 2026, accelerated our revenue growth resulting in a 17% volume increase."
• "While the speed and magnitude of the volume growth stressed our supply chain, I'm proud of the team for exceeding our production targets to support this growth and confident in our ability to return to planned gross margin expansion activities by mid-2026."
• "Our new business pipeline and category demand are exceeding expectations. Customers are demanding additional capacity at a rate and speed we had not anticipated."
• "Accordingly, we are announcing a new aseptic manufacturing line at our Midlothian, Texas facility that is already over 50% subscribed and will come online in late 2026. Along with the previously announced fruit snack line in Omak, Washington, we are positioned to meet expected market demand through the end of 2028."

Industry Context

The announcement reflects strong underlying demand for plant-based beverages, broths, and better-for-you snacks, indicating favorable category tailwinds. SunOpta's strategic investments in new manufacturing capacity, such as the aseptic line in Midlothian, are a direct response to this robust market demand, positioning the company to capitalize on continued growth in the health and wellness food sector.

Stakeholder Impact

• Shareholders: Strong revenue growth and future capacity expansion offer long-term potential, but the lowered 2025 Adjusted EBITDA outlook and operational challenges introduce near-term uncertainty.
• Customers: New capacity investments aim to meet increasing demand, but current supply chain stress and temporary volume limitations from the wastewater issue could impact service levels in the short term.
• Employees: Investments in labor and infrastructure are noted, but there were also severance costs associated with the exit from aseptic totes packaging.
• Creditors: Net leverage improved slightly to 2.8x, and the company expects to maintain this ratio, indicating stable debt management.

Next Steps

• Return to planned gross margin expansion activities by mid-2026.
• Bring the new aseptic manufacturing line at the Midlothian, Texas facility online in late 2026.
• Continue to monitor and mitigate tariff exposure through alternative sourcing and pricing strategies.
• Host a conference call on November 5, 2025, to discuss the third quarter financial results.

Key Dates

Recommendation

While SunOpta demonstrated robust revenue growth and is investing in future capacity to meet strong market demand, the significant reduction in its 2025 Adjusted EBITDA outlook due to supply chain stress and operational issues indicates near-term profitability challenges. The long-term growth potential is attractive, but current headwinds suggest a 'hold' position until there is clearer evidence of margin recovery and operational efficiency improvements.

Keywords

SunOpta, STKL, SOY, Q3 2025, financial results, revenue growth, adjusted EBITDA, plant-based beverages, broths, fruit snacks, supply chain, manufacturing capacity, tariffs, food industry, corporate earnings